The Swiss bank believes the pharmaceutical giant’s 30-drug-trial pipeline makes it a “leading player in this field” and expects shares to rise by nearly 30%.
You are here: Home / UBS upgrades Big Pharma stock after shares drop on poor drug results
Market News and Views
The Swiss bank believes the pharmaceutical giant’s 30-drug-trial pipeline makes it a “leading player in this field” and expects shares to rise by nearly 30%.